What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
Here are the top 5 AJMC.com articles and videos on allergy for 2025.
The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...
High airway TSLP asthma is linked to severe disease, type 2 inflammation, and airway remodelling. Learn more about how TSLP may guide targeted treatment.
New Jersey-based pharma companies joined White House drug pricing deals aimed at lowering prescription drug costs under Trump’s policy.
MedPage Today on MSN
The Promise of Biomarkers to Direct Chronic Spontaneous Urticaria Therapy
Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
The Centers for Medicare & Medicaid Services released details of its proposal to address the expensive costs of Medicare Part B.
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback